MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data

These RWD from the FLEX Registry demonstrate that MPI is predictive of both DRFI prognosis and chemotherapy benefit in HR+HER2- EBC. (NCT03053193).